Heart and Blood Diseases

All Conditions

Symptoms and General Pathology

Coronary Artery Disease

Myocardial Ischemia

Coronary Disease

Ischemia

Heart Diseases

Arteriosclerosis

Arterial Occlusive Diseases

Vascular Diseases

Time between the dates of PCI and cancer surgery \<12 months

time between the dates of PCI and cancer surgery ≥12 months

To evaluate the association between time from PCI to cancer surgery and cardiovascular and oncologic outcomes in early-stage cancer patients, A retrospective, population-based cohort study was conducted using data from the Korean National Health Insurance Service (K-NHIS) database.

Early-stage-cancer patients with a history of PCI who underwent cancer surgery (N = 3621) were included. The patients were divided into two groups based on the time between the dates of PCI and cancer surgery (\&lt;12 months and ≥12 months). Patients were stratified into early-surgery and late-surgery, defined as patients who underwent surgery ≥1 and \&lt;1 month after cancer diagnosis. Outcomes included bleeding, spontaneous myocardial infarction (MI), repeat revascularization, cancer recurrence, and death.

Time From PCI to Cancer Surgery and Cardiovascular and Oncologic Outcomes

Association Between Time From PCI to Cancer Surgery and Cardiovascular and Oncologic Outcomes

Bleeding requiring transfusion was defined by the transfusion codes (X2021, X2022, X2031, X2032, X2091, X2092, X2111, X2112, X2131, X2132).

Spontaneous myocardial infarction (MI) was defined as hospitalization for MI (ICD-10 codes I21 and I22)

Repeat revascularization was defined as the presence of a procedure code after cancer surgery.

Cancer recurrence was defined as the presence of chemotherapy and/or radiation therapy that began more than 6 months after surgery completion.

Vital status was obtained from death certification collected by Statistics Korea at the Ministry of Strategy and Finance of South Korea.

Samsung Medical Center

Professor

Neoplasms

Digestive System Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Esophageal Squamous Cell Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

The patient underwent minimally invasive esophagectomy within 50 days after receiving neoadjuvant therapy

The patient underwent minimally invasive esophagectomy 50 days after receiving neoadjuvant therapy

Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage

Neoadjuvant chemradiotherapy

The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes

Minimally invasive esophagectomy

The optimal interval between neoadjuvant chemradiotherapy and esophagectomy is still a question that needs to be explored for patients with esophageal squamous cell carcinoma. In this study, based on previous studies, the investigators divided patients into two groups with a cutoff value of 50 days. By comparing the overall survival and disease-free survival of the entire population and non PCR population, the investigators ultimately obtained the optimal surgical timing suitable for clinical use

background：Neoadjuvant chemoradiotherapy has gradually become a first-line treatment for esophageal squamous cell carcinoma patients. After the completion of neoadjuvant chemoradiotherapy, patients usually undergo minimally invasive surgery to ensure complete removal of the tumor and lymphatic tissue. However, the optimal interval between neoadjuvant chemoradiotherapy and minimally invasive surgery is still an unknown factor, and whether it affects postoperative disease-free survival (DFS) and overall survival (OS) of patients remains unknown. Therefore, the main purpose of this study is to explore the specific impact of the interval between neoadjuvant chemoradiotherapy and minimally invasive surgery on patients, and to find the optimal interval time.

methods：Patients who underwent neoadjuvant chemoradiotherapy and minimally invasive surgery from two institutions between October 2010 and September 2019 were included in this study. The time interval is defined as the days between the last time a patient receives neoadjuvant chemoradiotherapy and the execution of surgery. Based on past research, the interval between the two groups was determined to be 50 days. The main research result is the OS and DFS of different interval groups in the overall population and non-PCR population. A multivariate Cox regression model was established to determine the main factors affecting Patient's OS and DFS.

Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma

Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy

Is there any tumor metastasis or recurrence in the overall population

Is there any tumor metastasis or recurrence in the non-PCR population

Is there any tumor metastasis or recurrence in the PCR population

Shanghai Zhongshan Hospital

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Time

Yayi He, MD, PHD

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients

detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression

detecting numbers of tumor mutations before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Shanghai Pulmonary Hospital, Shanghai, China

Prof. Caicun Zhou

Infections

Carcinoma, Hepatocellular

Hepatitis A

Hepatitis

Hepatitis B

Liver Diseases

Adenocarcinoma

Liver Neoplasms

Communicable Diseases

Blood-Borne Infections

Hepadnaviridae Infections

Virus Diseases

DNA Virus Infections

Hepatitis, Viral, Human

Hematinics

All Drugs and Chemicals

Liver Extracts

Those who did not deal with nodules and were closely followed up.

Patients with liver nodules were treated by radiofrequency ablation or/and surgery and so on.

Long term follow-up

Linhan Li, Master

Dazhi Zhang, Doctor

This study aims to explore whether there is difference in the incidence rate and incidence rate of HCC in patients with chronic hepatitis B who are screened for high risk of liver cancer. Whether the timely intervention can be used to reduce the incidence of HCC for the early screening and early warning patients can provide evidence-based medical evidence for the selection or adjustment of anti HBV drugs in high-risk patients with liver cancer. To provide evidence for whether patients with liver nodules at high risk of liver cancer need to deal with liver nodules in advance.

This study is a multicenter, prospective clinical study. Including the Second Affiliated Hospital of Chongqing Medical University, the Third Affiliated Hospital of Chongqing Medical University, the First Affiliated Hospital of Southwest Medical University, Chongqing public health treatment center and the Three Gorges central hospital.

Firstly, patients were screened for peripheral blood cfdna gene to screen patients with high risk of liver cancer. High risk patients were examined for high-precision HBV-DNA quantification, liver function, AFP, abdominal imaging (color Doppler ultrasound, CT or MR), blood map, HIV syphilis screening, anti HDV, anti HCV, etc. according to the results of high-precision HBV-DNA quantification (lower than the detection limit (\< 10 IU / ml), ≥ 10 IU / ml, non negative ones are uniformly called positive), and patients are divided into 2 groups according to the wishes of patients, with 50 cases in each group. The observation group includs those who did not deal with nodules and were closely followed up，another group is treatment group，includs those who with hepatic nodules were treated by radiofrequency ablation and/or surgery and so on. Follow up examinations were conducted every 3 months to the center. The follow-up period lasted for 3 years. Clinical data were recorded, incidence rate of liver cancer, occurrence time of liver cancer and incidence of adverse events in liver were recorded.

Research implementation process and route

1. Recruitment object: after the approval of the ethics committee, the recruitment was started in each experimental center, the basic information and various examination indexes of the patients were collected, and the patients were informed that they needed to go to the outpatient clinic of our hospital for follow-up examination every 3 months, with a total follow-up of 3 years.
2. Establishment of information archives: in addition to recording the basic information and examination results of patients, it also includes the time when patients should be followed up in our hospital. Contact and inform patients in advance before each follow-up time. At the same time, special clinical events during follow-up were recorded.
3. Statistical analysis: after a three-year follow-up, the data collected by each center were tested by t-test and multivariate Cox analysis to analyze the time when patients in each group developed into primary liver cancer and the incidence of primary liver cancer in each group.
4. Data to be collected: general medical history characteristics: medical record number, name, gender, age, disease degree (whether there is decompensation / compensation of liver cirrhosis, whether there is liver nodule, etc.), enrollment time, contact information, whether to drink alcohol and medication. Examination and inspection indicators: liver function, renal function, blood chart analysis, hepatitis B two half and half, anti HCV, anti HDV, AIDS syphilis screening, high precision HBV-DNA quantification, abdominal color Doppler ultrasound (if necessary CT or MR), liver transient elastography, liver cirrhosis patients need additional coagulation. Patients undergoing radiofrequency ablation or surgical treatment of liver nodules need to record the operation time and mode.
5. Follow up: after enrollment, the relevant examination indexes were rechecked every 3 months. The follow-up period was 3 years.
6. Patients with new liver diseases and decompensated complications of liver cirrhosis also need to be recorded.

Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma

Clinical Intervention Strategy for High-risk Hepatitis B Related Hepatocellular Carcinoma Based on Liquid Biopsy Screening Technique

The time of all patients when they were enrolled.

The time of the patients when they were diagnosed of liver cancer.

Chongqing Three Gorges Central Hospital

The Affiliated Hospital Of Southwest Medical University

Chongqing Public Health Medical Center

Zhang Dazhi,MD

Clinical Professor

Fatigue

Herbal and Botanical

Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times). Participants will also receive weekly tips to encourage a healthy lifestyle in cancer survivorship.

Participants will receive weekly tips to encourage healthy lifestyle behaviors in cancer survivorship.

12 weeks of time-restricted eating (10-hour window)

Time-restricted eating

Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks

Healthy lifestyle education

Amber Kleckner, PhD

This study will assess the feasibility of delivering a 12-week time-restricted eating intervention as well as the intervention's preliminary efficacy on persistent cancer-related fatigue among cancer survivors compared to a general health education control. Participants will be randomized 1:1 to one of two arms: time-restricted eating or control. Those in the intervention arm will self-select a 10-hour eating window in which to consume all food and beverages (water is allowed any time, black coffee and unsweetened tea are allowed in the morning). Both groups will receive weekly educational tips on healthy lifestyle behaviors in cancer survivorship. This study will also explore relationships between fatigue, circadian rhythm, and glucose metabolism.

The hypothesis is that recruitment will be feasible, and participants will adhere to time-restricted eating and complete study activities over the course of the 12 weeks. The second hypothesis is that time-restricted eating will lead to less fatigue at 12 weeks compared to the control, accounting for baseline fatigue levels.

Time-Restricted Eating to Address Persistent Cancer-Related Fatigue

Time-Restricted Eating to Address Persistent Cancer-Related Fatigue: The Fatigue REDuction After Cancer (FREDA) Trial

To assess feasibility, the percentage of participants who provide evaluable data regarding their eating window at baseline and 12 weeks will be assessed.

FACIT-F fatigue subscale scores will be compared for those in the time-restricted eating group vs. the control group at week 12, controlling for baseline levels. This questionnaire is 13-items long, and a higher score indicates less fatigue.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Time From PCI to Cancer Surgery and Cardiovascular and Oncologic Outcomes	NCT06357000	Coronary Artery... Cancer		18 Years -	Samsung Medical Center
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma	NCT06364566	Time	Neoadjuvant che... Minimally invas...	-	Shanghai Zhongshan Hospital
NGS Combined With RNAseq on Tumor Immune Escape in NSCLC	NCT03764917	Non-small Cell ...	Time	18 Years - 75 Years	Shanghai Pulmonary Hospital, Shanghai, China
Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma	NCT05256459	Time	Long term follo...	18 Years -	The Second Affiliated Hospital of Chongqing Medical University
Time-Restricted Eating to Address Persistent Cancer-Related Fatigue	NCT05256888	Neoplasms Therapy Fatigue Diet Therapy Time Survivorship Fasting, Interm...	Time-restricted... Healthy lifesty...	18 Years -	University of Maryland, Baltimore

Spots Global Cancer Trial Database for time

Every month we try and update this database with for time cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for time

Every month we try and update this database with for time cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for time cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.